ArticleClinical ophthalmology (Auckland, N.Z.)2025
Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess whether switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) improves injection intervals, disease activity, and anatomical/functional outcomes in wet age-related macular degeneration (wAMD). Methods: This multicenter retrospective study included patients aged ≥50 years with active wAMD, baseline visual acuity (VA) 35-70, lesion size ≤8 disc areas, and submacular hemorrhage ≤25%. All had prior ranibizumab and were switched to brolucizumab for suboptimal response. VA and central retinal thickness (CRT) were recorded at switch, 6, and 12 months. Injection counts before and after switching were analyzed. Safety was monitored for intraocular inflammation (IOI) and discontinuation. Results: Seventy-nine eyes (75 patients) were enrolled; 66 eyes (60 patients, median age 75.0 years [IQR: 70.0-80.0]) completed 12 months. Patients received median 12.0 ranibizumab injections [IQR: 8.0-19.0] pre-switch and 5.0 brolucizumab injections [IQR: 4.0-6.0] post-switch. Median switch VA was 50.0 letters [IQR: 36.5-63.0]; CRT was 319.0 µm [IQR: 258.0-393.0]. At 6 months, VA improved to 51.0 [IQR: 38.0-66.5] ( Conclusion: Switching to brolucizumab reduced CRT, modestly improved or stabilized VA, and decreased injection frequency with acceptable safety. Limitations include retrospective design, modest sample size, and exclusion of poor visual outcomes, potentially introducing selection bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.